Acer Therapeutics Inc.

OTCPK:ACER Lagerbericht

Marktkapitalisierung: US$19.7m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Acer Therapeutics Management

Management Kriterienprüfungen 3/4

Acer Therapeutics CEO ist Chris Schelling , ernannt in Dec 2013, hat eine Amtszeit von 9.92 Jahren. Die jährliche Gesamtvergütung beträgt $834.28K , bestehend aus 59.9% Gehalt und 40.1% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 11.09% der Aktien des Unternehmens, im Wert von $2.18M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 4.2 Jahre bzw. 6.2 Jahre.

Wichtige Informationen

Chris Schelling

Geschäftsführender

US$834.3k

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts59.93%
Amtszeit als Geschäftsführer9.9yrs
Eigentum des Geschäftsführers11.1%
Durchschnittliche Amtszeit des Managements4.2yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder6.2yrs

Jüngste Management Updates

Analyseartikel • Feb 25

Need To Know: Acer Therapeutics Inc. (NASDAQ:ACER) Insiders Have Been Buying Shares

We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also...

Recent updates

Seeking Alpha • Oct 05

Acer Therapeutics to develop ACER-801 for post-traumatic stress disorder treatment

Acer Therapeutics (NASDAQ:ACER) said on Wednesday it was expanding ACER-801 into a new indication, to reduce the frequency and severity of acute stress disorder and post-traumatic stress disorder. (ACER) is trading 3.5% higher premarket. In a study conducted in thousands of genes that were activated in the brains of mice following fear conditioning events showed the drug was able to block fear memory consolidation shortly after exposure to a trauma. ACER-801 is a non-hormonal drug designed as a selective non-peptide neurokinin 3 receptor (NK3R) antagonist. "While the role of the NK3R pathway in the hypothalamus to manage thermoregulation is well-established in clinical trials, this opportunity explores an entirely different mechanism of action for the drug. We look forward to presenting our clinical development plan for ACER-801 for the reduction of frequency and severity of PTSD in the near future," the company said. Acute stress disorder refers to the body’s immediate response to trauma, whereas PTSD is defined as the long-term effects of trauma. The company is also developing the drug for induced Vasomotor Symptoms, which is hot flashes, flushing, and night sweats — that tend to occur in or around menopause.
Seeking Alpha • Aug 12

Acer, Relief's metabolic disorder therapy ACER-001 gets orphan drug status in EU

The European Commission granted orphan medicinal product designation to Acer Therapeutics (NASDAQ:ACER) and Relief Therapeutics' (OTCQB:RLFTF) (OTCQB:RLFTY) ACER-001 (sodium phenylbutyrate) to treat patients with Maple Syrup Urine Disease (MSUD). ACER-001 was had received the U.S. Food and Drug Administration's (FDA) orphan drug designation for MSUD in 2014, the companies said in an Aug. 12 press release. MSUD is a rare genetic metabolic disorder characterized by deficiency of an enzyme complex which is required to break down certain amino acids in the body. In the EU, the orphan drug status is granted to therapies aimed at treating or preventing a serious or life-threatening disease which affects not more than five in 10K people in the EU. The designation has benefits, including up to 10 years of market exclusivity for the product, if approved. ACER +6.76% to $1.58 premarket Aug. 12
Seeking Alpha • Jul 28

FDA accepts Acer's resubmitted U.S. marketing application for urea cycle disorder therapy

Acer Therapeutics (NASDAQ:ACER) and partner Relief Therapeutics (OTCQB:RLFTF) (OTCQB:RLFTY) on Thursday said the U.S. Food and Drug Administration (FDA) had accepted the companies' resubmission of their new drug application for their ACER-001 treatment for patients with urea cycle disorders. The FDA designated the new drug application (NDA) as a class 2 resubmission and said it would review the application by Jan. 15, 2023, or the so-called Prescription Drug User Fee Act date. Despite the news, ACER stock had fallen 4.2% to $1.37 in premarket trading. The FDA's acceptance of the NDA comes 10 days after ACER and RLFTF resubmitted the application. The NDA had been initially declined by the FDA in June as the agency's field investigator had been unable to complete inspection of ACER's third-party contract packaging manufacturer.
Seeking Alpha • Jul 18

Acer resubmits U.S. marketing application for urea cycle disorder therapy

Newton, Massachusetts-based Acer Therapeutics (NASDAQ:ACER) announced on Monday that the company resubmitted its New Drug Application (NDA) seeking FDA approval of ACER-001 oral suspension for the treatment of patients with urea cycle disorders (UCDs). Also known as sodium phenylbutyrate, ACER-001 is undergoing studies as a treatment for various inborn errors of metabolism such as UCDs. In June, Acer (ACER) announced that the FDA issued a Complete Response Letter (CRL), rejecting the marketing approval of the drug, citing the need for satisfactory inspection of its third-party contract packaging manufacturer. In the resubmission, the company has informed the FDA that the contract manufacturer in question is ready for inspections. In addition to labeling and other standard updates to the original filing, the resubmitted NDA included the nonclinical info that the FDA requested but categorized as “not an approvability issue” in the CRL. A decision on the acceptance of the NDA is expected within 14 calendar days of the submission. Last month, the shares of Acer (ACER) and its partner Relief Therapeutics (OTCQB:RLFTF) fell on the announcement of FDA rejection of ACER-001.
Analyseartikel • Feb 11

Companies Like Acer Therapeutics (NASDAQ:ACER) Can Afford To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Seeking Alpha • Aug 31

Acer Therapeutics: Deriving Value By Developing Therapies For Rare Diseases

Acer Therapeutics is a pharmaceutical company that acquires, develops and seeks to commercialize therapies for serious, rare, and life-threatening diseases. Acer submitted an NDA for its lead drug candidate ACER-001 for treatment of UCDs in early August. Acer expects notification regarding potential acceptance for filing from the FDA approximately 60 days after NDA submission and subsequent substantive review. If approved, Acer could launch ACER-001 in mid-2022. Other than UCDs, Acer is developing therapies for MSUD, iVMS, vEDS, and infectious diseases. All these diseases have a market that is niche and untapped, characterized by low competition. Assuming a base case revenue of $40 million in 2022 and a P/S ratio of 5.0x, the company’s intrinsic value would be ~$122 million or $8.70 per share, indicating an upside close to 3.5x.
Analyseartikel • May 20

We're Not Very Worried About Acer Therapeutics' (NASDAQ:ACER) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analyseartikel • Feb 25

Need To Know: Acer Therapeutics Inc. (NASDAQ:ACER) Insiders Have Been Buying Shares

We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also...

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Chris Schelling im Vergleich zu den Einnahmen von Acer Therapeutics verändert?
DatumGesamtvergütungGehaltUnternehmensgewinne
Jun 30 2023n/an/a

-US$39m

Mar 31 2023n/an/a

-US$33m

Dec 31 2022US$834kUS$500k

-US$26m

Sep 30 2022n/an/a

-US$21m

Jun 30 2022n/an/a

-US$20m

Mar 31 2022n/an/a

-US$20m

Dec 31 2021US$552kUS$436k

-US$15m

Sep 30 2021n/an/a

-US$17m

Jun 30 2021n/an/a

-US$20m

Mar 31 2021n/an/a

-US$23m

Dec 31 2020US$676kUS$436k

-US$23m

Sep 30 2020n/an/a

-US$22m

Jun 30 2020n/an/a

-US$21m

Mar 31 2020n/an/a

-US$26m

Dec 31 2019US$1mUS$436k

-US$29m

Sep 30 2019n/an/a

-US$33m

Jun 30 2019n/an/a

-US$31m

Mar 31 2019n/an/a

-US$25m

Dec 31 2018US$550kUS$400k

-US$21m

Sep 30 2018n/an/a

-US$17m

Jun 30 2018n/an/a

-US$17m

Mar 31 2018n/an/a

-US$15m

Dec 31 2017US$585kUS$117k

-US$14m

Sep 30 2017n/an/a

-US$12m

Jun 30 2017n/an/a

-US$11m

Mar 31 2017n/an/a

-US$9m

Dec 31 2016US$469kUS$469k

-US$7m

Vergütung im Vergleich zum Markt: ChrisDie Gesamtvergütung ($USD834.28K) liegt im Durchschnitt der Unternehmen ähnlicher Größe auf dem Markt US ($USD649.34K).

Entschädigung vs. Einkommen: ChrisDie Bezüge der Mitarbeiter sind gestiegen, während das Unternehmen unrentabel ist.

Geschäftsführer

Chris Schelling (47 yo)

9.9yrs
Amtszeit
US$834,280
Vergütung

Mr. Christopher Schelling, also known as Chris, Founded Acer Therapeutics Inc. in December 2013 and has been its President and Chief Executive Officer since September 2017 and served as its Chief Operating...

Führungsteam

NamePositionAmtszeitVergütungEigentümerschaft
Christopher Schelling
Founder9.9yrsUS$834.28k11.09%
$ 2.2m
Harry Palmin
Chief Financial Officer7.8yrsUS$592.59k0.51%
$ 100.6k
Adrian Quartel
Chief Medical Officer1.8yrsUS$857.63k0%
$ 0
Tanya Hayden
Chief Operating Officer1.4yrskeine Datenkeine Daten
John Klopp
Chief Technical Officer4.2yrskeine Datenkeine Daten
Donald Joseph
Chief Legal Officer & Secretary5.6yrsUS$490.28kkeine Daten
Bernie Paul
Chief People Officer3.1yrskeine Datenkeine Daten
Jefferson Davis
Chief Business Officer2.8yrsUS$634.80k0.29%
$ 57.6k
Jason Kneeland
VP of Finance & Controller6yrskeine Datenkeine Daten
4.2yrs
Durchschnittliche Betriebszugehörigkeit
54.5yo
Durchschnittliches Alter

Erfahrenes Management: ACERDas Führungsteam des Unternehmens gilt als erfahren (4.2 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

NamePositionAmtszeitVergütungEigentümerschaft
Christopher Schelling
Founder6.2yrsUS$834.28k11.09%
$ 2.2m
Stephen Aselage
Independent Chairman of the Board6.2yrsUS$104.95k1.98%
$ 389.2k
Michelle Griffin
Independent Director6.2yrsUS$88.08k0%
$ 0
Stuart J. Swiedler
Member of the Scientific Advisory Boardno datakeine Datenkeine Daten
John Dunn
Independent Director6.2yrsUS$84.95k0.11%
$ 22.0k
Thomas Fleming
Member of the Scientific Advisory Boardno datakeine Datenkeine Daten
Jason Amello
Independent Director6.2yrsUS$83.08k0%
$ 0
Marlene Haffner
Member of the Scientific Advisory Boardno datakeine Datenkeine Daten
Gerard Berry
Member of the Scientific Advisory Boardno datakeine Datenkeine Daten
6.2yrs
Durchschnittliche Betriebszugehörigkeit
66yo
Durchschnittliches Alter

Erfahrener Vorstand: ACERDie Vorstandsmitglieder gelten als erfahren (6.2 Jahre durchschnittliche Amtszeit).

Unternehmensanalyse und Finanzdaten Status

DatenZuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse2023/11/20 17:15
Aktienkurs zum Tagesende2023/11/17 00:00
Gewinne2023/06/30
Jährliche Einnahmen2022/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

PaketDatenZeitrahmenBeispiel US-Quelle *
Finanzdaten des Unternehmens10 Jahre
  • Gewinn- und Verlustrechnung
  • Kapitalflussrechnung
  • Bilanz
Konsensschätzungen der Analysten+3 Jahre
  • Finanzielle Vorausschau
  • Kursziele der Analysten
Marktpreise30 Jahre
  • Aktienkurse
  • Dividenden, Splits und Aktionen
Eigentümerschaft10 Jahre
  • Top-Aktionäre
  • Insiderhandel
Verwaltung10 Jahre
  • Das Führungsteam
  • Direktorium
Wichtige Entwicklungen10 Jahre
  • Ankündigungen des Unternehmens

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Details des Analysemodells, das zur Erstellung dieses Berichts verwendet wurde, sind auf unserer GitHub-Seite verfügbar. Außerdem haben wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf YouTube.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Acer Therapeutics Inc. wird von 8 Analysten beobachtet. 2 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

AnalystEinrichtung
Kumaraguru RajaBrookline Capital Markets
Constantine DavidesD. Boral Capital LLC.
Vernon BernardinoH.C. Wainwright & Co.